PortalPublikationenDydrogesterone: pharmacological profile and mechanism of act...

Dydrogesterone: pharmacological profile and mechanism of action as luteal phase support in assisted reproduction

Standard

Dydrogesterone: pharmacological profile and mechanism of action as luteal phase support in assisted reproduction. / Griesinger, Georg; Tournaye, Herman; Macklon, Nick; Petraglia, Felice; Arck, Petra; Blockeel, Christophe; van Amsterdam, Peter; Pexman-Fieth, Claire; Fauser, Bart Cjm.

in: REPROD BIOMED ONLINE, Jahrgang 38, Nr. 2, 38(2), 01.02.2019, S. 249-259.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung

Harvard

Griesinger, G, Tournaye, H, Macklon, N, Petraglia, F, Arck, P, Blockeel, C, van Amsterdam, P, Pexman-Fieth, C & Fauser, BC 2019, 'Dydrogesterone: pharmacological profile and mechanism of action as luteal phase support in assisted reproduction', REPROD BIOMED ONLINE, Jg. 38, Nr. 2, 38(2), S. 249-259. https://doi.org/10.1016/j.rbmo.2018.11.017

APA

Griesinger, G., Tournaye, H., Macklon, N., Petraglia, F., Arck, P., Blockeel, C., van Amsterdam, P., Pexman-Fieth, C., & Fauser, B. C. (2019). Dydrogesterone: pharmacological profile and mechanism of action as luteal phase support in assisted reproduction. REPROD BIOMED ONLINE, 38(2), 249-259. [38(2)]. https://doi.org/10.1016/j.rbmo.2018.11.017

Vancouver

Griesinger G, Tournaye H, Macklon N, Petraglia F, Arck P, Blockeel C et al. Dydrogesterone: pharmacological profile and mechanism of action as luteal phase support in assisted reproduction. REPROD BIOMED ONLINE. 2019 Feb 1;38(2):249-259. 38(2). https://doi.org/10.1016/j.rbmo.2018.11.017

Bibtex

@article{ca972de3872644a5ba293f38ea83830c,
title = "Dydrogesterone: pharmacological profile and mechanism of action as luteal phase support in assisted reproduction",
abstract = "The pharmacological and physiological profiles of progestogens used for luteal phase support during assisted reproductive technology are likely to be important in guiding clinical choice towards the most appropriate treatment option. Various micronized progesterone formulations with differing pharmacological profiles have been investigated for several purposes. Dydrogesterone, a stereoisomer of progesterone, is available in an oral form with high oral bioavailability; it has been used to treat a variety of conditions related to progesterone deficiency since the 1960s and has recently been approved for luteal phase support as part of an assisted reproductive technology treatment. The primary objective of this review is to critically analyse the clinical implications of the pharmacological and physiological properties of dydrogesterone for its uses in luteal phase support and in early pregnancy.",
keywords = "Journal Article, Review",
author = "Georg Griesinger and Herman Tournaye and Nick Macklon and Felice Petraglia and Petra Arck and Christophe Blockeel and {van Amsterdam}, Peter and Claire Pexman-Fieth and Fauser, {Bart Cjm}",
note = "Copyright {\textcopyright} 2018 Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights reserved.",
year = "2019",
month = feb,
day = "1",
doi = "10.1016/j.rbmo.2018.11.017",
language = "English",
volume = "38",
pages = "249--259",
journal = "REPROD BIOMED ONLINE",
issn = "1472-6483",
publisher = "Elsevier",
number = "2",

}

RIS

TY - JOUR

T1 - Dydrogesterone: pharmacological profile and mechanism of action as luteal phase support in assisted reproduction

AU - Griesinger, Georg

AU - Tournaye, Herman

AU - Macklon, Nick

AU - Petraglia, Felice

AU - Arck, Petra

AU - Blockeel, Christophe

AU - van Amsterdam, Peter

AU - Pexman-Fieth, Claire

AU - Fauser, Bart Cjm

N1 - Copyright © 2018 Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights reserved.

PY - 2019/2/1

Y1 - 2019/2/1

N2 - The pharmacological and physiological profiles of progestogens used for luteal phase support during assisted reproductive technology are likely to be important in guiding clinical choice towards the most appropriate treatment option. Various micronized progesterone formulations with differing pharmacological profiles have been investigated for several purposes. Dydrogesterone, a stereoisomer of progesterone, is available in an oral form with high oral bioavailability; it has been used to treat a variety of conditions related to progesterone deficiency since the 1960s and has recently been approved for luteal phase support as part of an assisted reproductive technology treatment. The primary objective of this review is to critically analyse the clinical implications of the pharmacological and physiological properties of dydrogesterone for its uses in luteal phase support and in early pregnancy.

AB - The pharmacological and physiological profiles of progestogens used for luteal phase support during assisted reproductive technology are likely to be important in guiding clinical choice towards the most appropriate treatment option. Various micronized progesterone formulations with differing pharmacological profiles have been investigated for several purposes. Dydrogesterone, a stereoisomer of progesterone, is available in an oral form with high oral bioavailability; it has been used to treat a variety of conditions related to progesterone deficiency since the 1960s and has recently been approved for luteal phase support as part of an assisted reproductive technology treatment. The primary objective of this review is to critically analyse the clinical implications of the pharmacological and physiological properties of dydrogesterone for its uses in luteal phase support and in early pregnancy.

KW - Journal Article

KW - Review

U2 - 10.1016/j.rbmo.2018.11.017

DO - 10.1016/j.rbmo.2018.11.017

M3 - SCORING: Review article

C2 - 30595525

VL - 38

SP - 249

EP - 259

JO - REPROD BIOMED ONLINE

JF - REPROD BIOMED ONLINE

SN - 1472-6483

IS - 2

M1 - 38(2)

ER -